Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors

Published:2020-03-06 Issue:10 Volume:126 Page:2288-2295
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Petrillo Laura A.¹²^ORCID,El‐Jawahri Areej²³^ORCID,Nipp Ryan D.²³^ORCID,Lichtenstein Morgan R. L.⁴^ORCID,Durbin Sienna M.²^ORCID,Reynolds Kerry L.²³^ORCID,Greer Joseph A.²⁵^ORCID,Temel Jennifer S.²³^ORCID,Gainor Justin F.²³^ORCID

Affiliation:

1. Department of Medicine Division of Palliative Care and Geriatrics Massachusetts General Hospital Boston Massachusetts

2. Harvard Medical School Boston Massachusetts

3. Department of Medicine Division of Hematology and Oncology Massachusetts General Hospital Boston Massachusetts

4. Department of Medicine Division of Hematology and Oncology Columbia University Medical Center New York New York

5. Department of Psychiatry Massachusetts General Hospital Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32782

Reference32 articles.

1. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

5. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-component paclitaxel −loaded β-elemene nanoemulsion by transferrin modification enhances anti-non-small-cell lung cancer treatment;International Journal of Pharmaceutics;2024-09

2. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy;American Journal of Clinical Oncology;2024-08-01

3. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

4. Learning About and Living With Toxicity: A Qualitative Study of Patients Receiving Immune Checkpoint Inhibitors For Melanoma or Lung Cancer and Their Caregivers;2024-07-04

5. The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer;Cancer Immunology, Immunotherapy;2024-07-02